drugset / Trial / NCT00436033

A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome

NCT00436033

Phase 3 Completed 1429 enrolled Pierre Fabre Laboratories
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.

Timeline

Start
2006-02
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Milnacipran Other / unclassified 200 mg

Indications